These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25287898)

  • 1. Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan.
    Abe M; Oikawa O; Okada K; Soma M
    J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):159-64. PubMed ID: 25287898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.
    Furuhashi M; Moniwa N; Mita T; Fuseya T; Ishimura S; Ohno K; Shibata S; Tanaka M; Watanabe Y; Akasaka H; Ohnishi H; Yoshida H; Takizawa H; Saitoh S; Ura N; Shimamoto K; Miura T
    Am J Hypertens; 2015 Jan; 28(1):15-21. PubMed ID: 24842388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.
    Agata J; Ura N; Yoshida H; Shinshi Y; Sasaki H; Hyakkoku M; Taniguchi S; Shimamoto K
    Hypertens Res; 2006 Nov; 29(11):865-74. PubMed ID: 17345786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
    Arai K; Morikawa Y; Ubukata N; Sugimoto K
    Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood Pressure-Independent Effect of Olmesartan on Albuminuria in Mice Overexpressing Renin.
    Ichikawa H; Narita I; Narita M; Tanno T; Yokono Y; Kimura Y; Tanaka M; Osanai T; Okumura K; Tomita H
    Int Heart J; 2018 Nov; 59(6):1445-1453. PubMed ID: 30369568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
    Tsutamoto T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
    Hypertens Res; 2010 Feb; 33(2):118-22. PubMed ID: 19927151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
    Nakamura T; Inoue T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Node K
    Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).
    Imai E; Haneda M; Yamasaki T; Kobayashi F; Harada A; Ito S; Chan JC; Makino H
    Hypertens Res; 2013 Dec; 36(12):1051-9. PubMed ID: 24026038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
    Ohtomo S; Ito M; Izuhara Y; Van Ypersele De Strihou C; Miyata T
    Nephrology (Carlton); 2008 Dec; 13(6):517-21. PubMed ID: 18363646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
    Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice.
    Shiota A; Yamamoto K; Ohishi M; Tatara Y; Ohnishi M; Maekawa Y; Iwamoto Y; Takeda M; Rakugi H
    Hypertens Res; 2010 Apr; 33(4):298-307. PubMed ID: 20186149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
    Nakamura T; Fujiwara N; Sato E; Ueda Y; Sugaya T; Koide H
    Kidney Blood Press Res; 2010; 33(3):213-20. PubMed ID: 20588058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade.
    Igase M; Kohara K; Nagai T; Miki T; Ferrario CM
    Hypertens Res; 2008 Mar; 31(3):553-9. PubMed ID: 18497476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
    Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
    Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease.
    Abe M; Maruyama N; Oikawa O; Maruyama T; Okada K; Soma M
    Scand J Clin Lab Invest; 2015 Sep; 75(5):421-7. PubMed ID: 26067610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary angiotensin converting enzyme 2 increases in patients with type 2 diabetic mellitus.
    Liang Y; Deng H; Bi S; Cui Z; A L; Zheng D; Wang Y
    Kidney Blood Press Res; 2015; 40(2):101-10. PubMed ID: 25791940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury.
    Wong DW; Oudit GY; Reich H; Kassiri Z; Zhou J; Liu QC; Backx PH; Penninger JM; Herzenberg AM; Scholey JW
    Am J Pathol; 2007 Aug; 171(2):438-51. PubMed ID: 17600118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.